Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy?

Authors


  • Potential conflict of interest: Lawrence Serfaty: consulting, advisory committees or review panels (Axcan Pharma, Bristol-Myers Squibb, Gilead, „GlaxoSmithKline, Janssen, MSD, Pfizer, Roche, Schering-Plough, Tibotec, Vertex), grant/research support (Roche; Schering-Plough), speaking and teaching (Axcan Pharma, Bristol-Myers Squibb, Gilead, Janssen, MSD, Roche, Schering-Plough, Vertex). Olivier Chazouilléres: grants (Roche, MSD). Alina Pascale: no conflict of interest.

No abstract is available for this article.

Ancillary